Infection-Decline Correlation Study

1 Background and Rationale

Clinical experience suggests that infections trigger PEM and may cause persistent functional decline in ME/CFS patients. However, the quantitative relationship between infection frequency and cumulative baseline functional decline has not been formally characterized. This prospective cohort study would establish whether infections produce irreversible baseline declines and whether early antiviral intervention can mitigate these effects.

2 Study Design

2.1 Design Overview

Prospective observational cohort study with standardized infection documentation, treatment timing records, and quarterly functional assessments over 3 years.

2.2 Participants

  • n=200 adults and adolescents with ME/CFS (ages 12–65)
  • Disease duration \(\geq\) 6 months
  • Mild to moderate severity (able to participate in quarterly assessments)
  • History of \(\geq\) 2 documented infections in prior 12 months (to enrich for infection-prone individuals)
  • Ability to document infections with temporal precision

2.3 Exclusion Criteria

  • Immunosuppressive therapy or active malignancy
  • Unable to provide infection documentation
  • Severe psychiatric comorbidity precluding informed consent

3 Assessment Schedule

  • Baseline: Full clinical assessment, baseline functional status (Bell scale, SF-36, DSQ-PEM)
  • Quarterly (every 3 months): Functional reassessment, infection history review
  • Continuous: Infection documentation by patient (illness diary or symptom tracker app) Duration: 3 years per participant.

4 Infection Documentation Protocol

Participants document each illness with:

  • Date of symptom onset
  • Presumed pathogen (viral vs. bacterial, if identifiable)
  • Symptoms (upper respiratory, gastrointestinal, systemic)
  • Severity (1–10 scale)
  • Time from symptom onset to antiviral treatment initiation (if applicable)
  • Antiviral agents used and duration
  • PEM response (crash triggered yes/no, severity if yes, recovery duration)
  • Estimated baseline functional impact 2 weeks post-infection recovery

5 Measures

5.1 Functional Status

  • Bell Disability Scale (primary functional outcome)
  • SF-36 (secondary functional outcome)
  • DSQ-PEM (symptom burden)
  • Days per month with significant activity limitation
  • Employment/educational status

5.2 Infection Data

  • Cumulative infection count over study period
  • Infection type distribution
  • Treatment timing for each infection
  • Antiviral vs. untreated infections
  • Infection severity distribution

5.3 Infection Prevention Practices

  • Quarterly questionnaire on hygiene practices (handwashing frequency, sick contacts avoidance, masking in high-risk settings, etc.)
  • Categorization: Standard hygiene vs. intensive prevention practices

6 Outcomes

6.1 Primary Outcome

Cumulative functional decline (baseline to 3-year Bell scale change) as a function of cumulative infection burden over 3 years.

6.2 Secondary Outcomes

  • Functional decline per infection (Bell scale change per documented illness)
  • Impact of treatment timing: Functional decline in \(<\) 24h-treated infections vs. delayed treatment vs. untreated
  • Effect of infection prevention: 3-year Bell scale change in intensive prevention vs. standard practice groups
  • Infection frequency: Comparison of high-infection vs. low-infection subgroups in matched disease duration cohorts

6.3 Exploratory Outcomes

  • Dose-response relationship: Does infection count linearly predict functional decline?
  • Threshold effect: Is there a critical infection frequency beyond which decline accelerates?
  • Infection type specificity: Do certain pathogen types cause greater decline?

7 Analysis Plan

  • Linear regression: Bell scale decline (outcome) vs. cumulative infection count (predictor), adjusted for baseline severity, age, sex, disease duration
  • Stratified analysis: Compare decline slopes between early-treatment (\(<\) 24h) vs. delayed/untreated groups
  • Prevention effect: ANCOVA comparing 3-year Bell scale change between intensive prevention and standard hygiene groups, adjusted for baseline infection frequency
  • Time-varying analyses: Does infection burden in years 0–1 predict steeper decline in years 1–3?
  • Logistic regression: Predictors of experiencing \(\geq\) 1 major functional decline event

8 Sample Size Justification

With n=200 and 12 assessment points over 3 years (2,400 observations):

  • 80% power to detect linear association between infection count and Bell scale decline (regression \(\beta\)=1.5 points per infection, SD=10) at \(\alpha\)=0.05
  • Adequate power for subgroup comparisons (n \(\geq\) 50 per treatment timing category)

9 Expected Outcomes and Implications

If hypothesis is supported:

  • Quantifies functional cost of infections in ME/CFS

  • Validates aggressive infection prevention as disease-modifying strategy

  • Establishes early antiviral treatment as standard of care intervention

  • Informs prognostic counseling about long-term functional trajectory

  • May support use of prophylactic antivirals in high-risk patients If infections do not predict decline:

  • Suggests infection-triggered decline is less significant than currently believed

  • Redirects focus toward other mechanisms of disease progression

  • Questions cost-benefit of intensive infection prevention practices